FIVE PRIME THERAPEUTICS (FPRX) Covered Calls

FIVE PRIME THERAPEUTICS covered calls Five Prime Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in discovering & developing novel protein therapeutics to improve lives of patients with serious diseases. Its product include FP-1039/GSK3052230, FPA008 & FPA144.

You can sell covered calls on FIVE PRIME THERAPEUTICS to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for FPRX (prices last updated Fri 4:16 PM ET):

FIVE PRIME THERAPEUTICS (FPRX) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
14.30 +0.06 14.38 19.50 290K - 0.5B
Covered Calls For FIVE PRIME THERAPEUTICS (FPRX)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
Nov 16 15 0.85 18.65 -19.6% -246.7%
Dec 21 15 1.25 18.25 -17.8% -101.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. The company advanced product candidates includes, FPA008, FPA144 and FP-1039/GSK3052230. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric (stomach) cancer. The FP-1039/GSK3052230 is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors. Five Prime Therapeutics was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, CA.